Hydrocortisone for Severe Pneumonia (REMAP-CAP), Intensive BP Control in Diabetes (BPROAD), Aldosterone Synthase Inhibitors for Hypertension (ADVANCE-HTN), Reduced-dose Apixaban for Cancer Associated Thrombosis (API-CAT)
About this episode
What do you do when most trials suggest benefit for an intervention, but then a new trial suggests harm? We thought steroids in pneumonia was a settled question, but REMAP-CAP had other plans!
We also review a new RCT for BP targets in patients with hypertension and diabetes, a new aldosterone synthase inhibitor for hypertension, and reduced dose apixaban for cancer-associated thrombosis.
Hydrocortisone for Severe CAP (REMAP-CAP)
Predicting Benefit of Corticosteroids in Pneumonia
Intensive BP Control in Patients with Diabetes (BPROAD)
Lorundrostat for Uncontrolled Hypertension (ADVANCE-HTN)
Reduced Dose Apixaban for Cancer Associated Thrombosis (API-CAT)
Music from Uppbeat (free for Creators!):
https://uppbeat.io/t/soundroll/dope
License code: NP8HLP5WKGKXFW2R
Get every episode summarized
Each time Last Week in Medicine publishes, we email you a written briefing from the transcript — the topics, who appeared, and any specific claims, with the ad reads skipped.
Email me new episodesFree for 3 shows. No card needed.
Hosts & guests
No transcript yet
This episode has not been transcribed. Request it and it moves to the front of the queue.
More episodes
More from Last Week in Medicine
Catheter Directed Fibrinolysis for Acute PE (HI-PEITHO), NEWS2 Plus Procalcitoni...
Last Week in Medicine
Bleeding Risk with Apixaban vs Rivaroxaban for Acute VTE (COBRRA), Left Atrial A...
Last Week in Medicine
2026 ACC/AHA Guidelines for Acute Pulmonary Embolism
Last Week in Medicine
Hematopoietic Stem Cell Gene Therapy for Cystinosis
Last Week in Medicine